Daniel Fero

Daniel Fero, Ph.D. has a diverse work experience in the life sciences, venture capital and healthcare industries. In 2020, they began working as Managing Director at OMX Ventures, a committed capital fund investing in life science tools and novel therapeutics companies. Daniel also began serving as Board Observer for Matterworks and Mythic Therapeutics, Inc. and Board Observer for Inscripta, Inc. In 2017, they began serving as Board Observer for Xeris Pharmaceuticals, Inc. and Twist Bioscience. In 2019, they began serving as Board Director for TARA Biosystems. In 2021, they began serving as Board Director for 1859 Inc. and Cellsonics Inc. From 2016-2018, they worked as a Healthcare Venture Capital Investor at Merieux Equity Partners.

Daniel Fero, Ph.D. earned their Bachelor of Arts degree in Biology from Rhode Island College and their Doctor of Philosophy degree in Biomedical Sciences from UC San Diego.